Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.74 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.74 |
| ▸ | P2RY12 known ✓ | Q9H244 | 2/20 | 0.74 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.74 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.45 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.45 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.45 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.74 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.74 |
| ▸ | DRD1 | P21728 | 2/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.74 |
| ▸ | HTR2B | P41595 | 2/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.74 |
| ▸ | THRB | P10828 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1989477 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Water SCHEMBL3377943 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Bromide SCHEMBL1130039 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Bromide SCHEMBL2486392 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Bromide SCHEMBL2489468 | 0.99 | ABCB11 (0.76) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| Hydrochloric Acid SCHEMBL7479212 | 0.98 | ABCB11 (0.74) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL4770 | 0.98 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL364610 | 0.98 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL19148650 | 0.98 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 | |
| SCHEMBL30277249 | 0.98 | ABCB11 (0.77) | ABCB11OPRM1CYP2C19ADRA2ACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1704152-A2 | CRYSTALLINE CLOPIDOGREL HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2006-09-27 | — | — | EP | claimed |
| US-20060154957-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-07-13 | — | — | US | claimed |
| WO-2006034451-A2 | CRYSTALLINE CLOPIDOGREL HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-03-30 | — | — | WO | claimed |
| EP-2291177-A2 | STABLE PHARMACEUTICAL COMPOSITIONS AND THEIR PROCESSES FOR PREPARATION SUITABLE FOR INDUSTRIAL SCALE | Farmaprojects, S.A. (ES) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009135646-A2 | STABLE PHARMACEUTICAL COMPOSITIONS AND THEIR PROCESSES FOR PREPARATION SUITABLE FOR INDUSTRIAL SCALE | FARMAPROJECTS, SA (ES) | 2009-11-12 | — | — | WO | disclosed |
| US-20090187022-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS. | 2009-07-23 | — | — | US | disclosed |
| US-20080306268-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-12-11 | — | — | US | disclosed |
| US-20080300409-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-12-04 | — | — | US | disclosed |
| EP-1704152-A2 | CRYSTALLINE CLOPIDOGREL HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2006-09-27 | — | — | EP | disclosed |
| US-20060154957-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-07-13 | — | — | US | disclosed |
| WO-2006034451-A2 | CRYSTALLINE CLOPIDOGREL HYDROBROMIDE AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154957-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | NUDT1, CYP2C9, PFKP | ADRA2A 187/4885CHRM2 443/4885P2RY12 9/4885 |
| US-20090187022-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | NUDT1, CYP2C9, PFKP | ADRA2A 187/4885CHRM2 443/4885P2RY12 9/4885 |
| US-20080306268-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | NUDT1, CYP2C9, PFKP | ADRA2A 187/4885CHRM2 443/4885P2RY12 9/4885 |
| US-20080300409-A1 | Crystalline clopidogrel hydrobromide and processes for preparation thereof | NUDT1, CYP2C9, PFKP | ADRA2A 187/4885CHRM2 443/4885P2RY12 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.